Search

Displaying results 4431 - 4440 of 8010 in total
  1. Drug

    Odronextamab

    go.drugbank.com/drugs/DB16684
    ApprovedInvestigational

    [A254192] Odronextamab received its first approval in the European Union on August 26, 2024, for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma … Odronextamab is a hinge-stabilized, fully human immunoglobulin G4 (IgG4)-based CD20×CD3 bispecific antibody currently evaluated for the treatment of relapsed/refractory (R/R) B-Cell non-Hodgkin lymphoma

  2. Drug

    PlasmaCord

    go.drugbank.com/drugs/DB16363
    Experimental

    PlasmaCord is platelet-poor plasma that is derived by fractionation from sterile umbilical cord and placental blood. … [L27581] It is developed by Cellpraxis and is currently being investigated against severe acute respiratory syndrome (SARS).

  3. Drug

    Mepenzolate

    go.drugbank.com/drugs/DB04843
    ApprovedWithdrawn

    It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications.

    Categories: Drugs for Functional Gastrointestinal Disorders
  4. Drug

    WP-1301

    go.drugbank.com/drugs/DB17702
    Experimental

    WP1301 is a synthetic peptide derived from hFVIII. It binds to an MHC class II molecule and is recognized by a Factor VIII-specific T cell.[L46138]

  5. Drug

    AEOL-10150

    go.drugbank.com/drugs/DB05874
    Experimental

    AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.

    Categories: Heterocyclic Compounds with 4 or More Rings
  6. Drug

    Verubecestat

    go.drugbank.com/drugs/DB12285
    Investigational

    In July 2013, Merck announced positive results for Phase Ib trials of Verubecestat. … In the study, administration of Verubecestat at doses of 12, 40 and 60 mg resulted in a dose-dependent and sustained reduction in the levels of Ab40, a measure of BACE1 activity, in CSF from baseline of

  7. Drug

    G4544

    go.drugbank.com/drugs/DB05244
    Experimental

    G4544 is an oral gallium compound that enables oral absorption of the active ingredient contained in Ganite™ (gallium nitrate injection). It targets bone tissue and is actively incorporated into bone mineral at sites where bone is metabo...

  8. Drug

    BF-1

    go.drugbank.com/drugs/DB06029
    Experimental

    BF-1 is an investigational 5-HT2B receptor antagonist developed for the prophylaxis of Migraines.

  9. Drug

    HGS-TR2J

    go.drugbank.com/drugs/DB05895
    Experimental

    It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.

  10. Drug

    Sulesomab

    go.drugbank.com/drugs/DB13976
    Approved

    Market product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.